Conference Coverage
Latest News
Oct 22, 2026 | Opinion
Engy Habashy, MD, on the role of androgens in GSM management
How PSMA-PET shapes staging and recurrence workup in prostate cancer
Oct 22, 2026
Michael Cookson, MD, reacts to Anktiva’s expanded approval in NMIBC
Oct 21, 2026
Q&A: Jeffrey Spier, MD, on ARPI fatigue and the case for dose reduction
Oct 21, 2026
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
Oct 21, 2026
Advertisement
Shorts
0:30
Correcting misconceptions about hormone therapy for GSM
11 hours ago
by
Engy Habashy, MD
1:29
How gravity instillation may improve gem/doce feasibility
2 days ago
by
Adam B. Weiner, MD(+1 more)
0:50
Expert: Anktiva approval sets precedent for papillary-only NMIBC
2 days ago
by
JJ Zhang, MD
0:22
Why underactive bladder stays under the radar
4 days ago
by
Ariana L. Smith, MD
0:42
The hidden long-term cost of OAB step therapy
7 days ago
by
Anjali Kapur, MD
0:35
PCARE and PROs: Addressing penile cancer's hidden burden
8 days ago
by
Luis G. Medina, MD
0:18
Exploring intranasal PDE5 inhibitor delivery for erectile dysfunction
8 days ago
by
Melissa Hadley Barrett
0:40
Challenging misconceptions about proximal shunting
10 days ago
by
Juan J. Andino, MD, MBA
1:12
Belzutifan plus lenvatinib offers a new option after IO in ccRCC
14 days ago
by
Mina M. Fam, MD
1:01
Decipher score may help guide short-term ADT use
15 days ago
by
Angela Jia, MD, PhD
From GSM guidance to HRT reform: A landmark year for women’s health
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
Inguinal lymph node dissection in penile cancer
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
Inside HoLEP: Irina Jaeger, MD, discusses patient selection and technique
Jaeger emphasizes that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication.
Videos
Urology Times Digital Edition
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.
The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Continuing Medical Education
Advertisement
All News
Advertisement
Take a look through some of the notable data presentations at this year's ESMO Congress.
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
The agency issued a PDUFA target action date of June 14, 2027.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years.
Vignesh Packiam, MD, discusses strategies to manage intravesical therapy toxicity in NMIBC, improve treatment tolerability, and preserve bladder function.
Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.
These FAQs outline key recommendations and practical takeaways from the AUA/SUFU/AUGS Genitourinary Syndrome of Menopause guideline.
Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.
Advertisement
Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical cystectomy.
FDA approves nogapendekin alfa inbakicept plus BCG for papillary-only BCG-unresponsive NMIBC
Published: | Updated:
This approval expands the label for nogapendekin alfa inbakicept to include patients with high-grade papillary-only tumors.
Melissa Hadley Barrett discusses real-world outcomes and tolerability of intranasal vardenafil for men with persistent erectile dysfunction despite prior standard therapy.
The completion of the first procedure marks the beginning of a controlled US commercial release.
Delayed diagnosis and skipped nodal staging worsen penile cancer outcomes, according to Luis G. Medina, MD.
Advertisement
Advertisement
Trending on Urology Times
1
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
2
How PSMA-PET shapes staging and recurrence workup in prostate cancer
3
ESMO 2026: Key presentations across genitourinary oncology
4
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
5